Study Title

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study Details

Description:

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.

Sponsor:

Memorial Sloan Kettering Cancer Center

Contacts:

Michael Morris, MD (Principal Investigator)

morrism@mskcc.org

646-422-4469

Josef Fox, MD

212-639-7371

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468